Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 76-89
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.76
Hsa_circ_0001658 accelerates the progression of colorectal cancer through miR-590-5p/METTL3 regulatory axis
Yang Lu, Xing-Ming Wang, Ze-Shu Li, Ai-Juan Wu, Wen-Xia Cheng
Yang Lu, Xing-Ming Wang, Ze-Shu Li, Ai-Juan Wu, Department of Oncology, PKUCare Luzhong Hospital, Zibo 255400, Shandong Province, China
Wen-Xia Cheng, Department of Oncology, Zibo Maternal and Child Health Hospital, Zibo 255095, Shandong Province, China
Author contributions: Lu Y designed the study, and wrote the manuscript; Lu Y, Wang X, and Li Z performed the research and collected data; Wu A and Cheng W contributed to the analysis and editing of the manuscript; All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of the PKUCare Luzhong Hospital (Approval No. 2020-L259).
Informed consent statement: The patients provided the informed written consent, and the resected pathological tissues were allowed to be used for pathological examination and biomedical research.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: This study was not involved any animal experiments.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yang Lu, MMed, Chief Physician, Department of Oncology, PKUCare Luzhong Hospital, No. 65 Taigong Road, Linzi District, Zibo 255400, Shandong Province, China. ly76730@163.com
Received: September 28, 2022
Peer-review started: September 28, 2022
First decision: October 21, 2022
Revised: November 1, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 15, 2023
ARTICLE HIGHLIGHTS
Research background

According to reports, circular RNAs (circRNAs) have a major role in cancer biology. Some circRNAs have been reported to function as oncogenes or tumor suppressors in colorectal cancer (CRC).

Research motivation

To further clarify the function of circRNAs for the development of CRC.

Research objectives

This paper aims to clarify the expression pattern, biological function, and underlying mechanism of circ_0001658 of CRC tumorigenesis.

Research methods

A series of in vitro experiments were performed. CircRNA expression profile using the GEO database was analyzed, and circRNAs with differential expression in CRC and normal tissue samples were detected. Quantitative real-time polymerase chain reaction and western blot were performed for the analysis of the expression of circ_0001658, miR-590-5p, and methyltransferase-like 3 (METTL3) mRNA expression levels in tissues and cells. Using Cell counting kit-8 and flow cytometry, cell proliferation, apoptosis, and the cell cycle were observed and studied. The targeting relations between circ_0001658, miR-590-5p, and METTL3 mRNA 3'UTR were under the verification of bioinformatics prediction and dual luciferase reporter gene assay.

Research results

circ_0001658 is significantly expressed in CRC tissues and cell lines. It enhances cancer cells' malignant biological activities, including proliferation, resistance to apoptosis, and cell cycle progression, via repressing miR-590-5p and up-regulating METTL3.

Research conclusions

circ_0001658 is an oncogenic circRNA in CRC, and it works as an endogenous RNA that competes with miR-590-5p and METTL3.

Research perspectives

circ_0001658 may have the potential to give and employ a therapeutic target and diagnostic biomarker for CRC.